Search

Showing total 1 results

Refine your results

1 results

1. BiTE immuno-oncology therapy appears safe with preliminary efficacy in mCRPC: More than 25% of patients show confirmed PSA response to investigational treatment.

Author

Kahl, Kristie L.

Subjects
*CANCER patient medical care, *IMMUNOTHERAPY, *T cells, *ADVERSE health care events, *CYTOKINE release syndrome
Abstract

The article discusses the research paper "Results from a phase I study of AMG 160, a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE) immune therapy for metastatic castration-resistant prostate cancer (mCRPC)," by Ben Tran, L. Horvath, T. Dorff, et al., which was presented at the 2020 European Society for Medical Oncology Virtual Congress held on September 19-21. Also detailed are the safety and the antitumor activity of AMG 160.

Published
2020